Agios Pharmaceuticals
AGIO
66 hedge funds and large institutions have $420M invested in Agios Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 20 closing their positions.
610% more capital inflows, than outflows
Capital inflows: $253M | Capital outflows: $35.6M
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
30.45% more ownership
Funds ownership: 27.89% → 58.35% (+30%)
8% less funds holding
Funds holding: 72 → 66 (-6)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
+$8.04M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.94M |
| 3 |
Jennison Associates
New York
|
+$3.01M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$2.85M |
| 5 |
ClearBridge Investments
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.1M |
| 2 |
PFM Health Sciences
San Francisco,
California
|
-$5.78M |
| 3 |
Deerfield Management
New York
|
-$4.22M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$2.91M |
| 5 |
Weiss Multi-Strategy Advisers
New York
|
-$2.25M |
AGIO Hedge Fund Activity: Q4 2013 in Review
66 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2013, worth a combined $420M — up 73% from $242M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AGIO and 14 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 28 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $8.04M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $6.1M sold.
- 66 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2013, down from 72 in Q3 2013.
- Funds reported $420M of Agios Pharmaceuticals stock for Q4 2013, up 73% quarter-over-quarter.
- 14 funds opened new Agios Pharmaceuticals positions in Q4 2013 and 20 closed out, a net change of -6 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2013 was BlackRock Fund Advisors, an estimated $8.04M added.
- The largest Agios Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $6.1M sold.
Based on aggregated 13F filings for Q4 2013.